Quantitative monitoring of WT-1 expression in peripheral blood before and after allogenenic stem cell transplantation for acute myeloid leukemia: a useful tool for early detection of minimal residual disease

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F13%3A00010522" target="_blank" >RIV/00023736:_____/13:00010522 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.4149/neo_2013_011" target="_blank" >http://dx.doi.org/10.4149/neo_2013_011</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2013_011" target="_blank" >10.4149/neo_2013_011</a>

Result language
angličtina
Original language name
Quantitative monitoring of WT-1 expression in peripheral blood before and after allogenenic stem cell transplantation for acute myeloid leukemia: a useful tool for early detection of minimal residual disease
Original language description
Overexpressed Wilms tumor gene 1 (WT1) has been found in a majority of patients with acute myeloid leukemia (AML). The aim of this study was to confirm the applicability of WT1 expression measurement as a marker of minimal residual disease (MRD). The expression of WT1 gene was measured by real-time polymerase chain reaction in peripheral blood (PB) according to European Leukemia Net (ELN) recommendations. The WT1 expression was related to the expression of a reference gene Abelson (ABL) and the resultswere calculated as a number of WT1 copies related to 104 copies of ABL gene. The upper normal limit of WT1 expression was set at 50 copies of WT1 to 104 copies of ABL. Morphological, flow cytometry and chimerism examinations were evaluated according to standard protocols.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NR8748" target="_blank" >NR8748: New molecular markers of residual disease in acute myeloid leukemia patients and of disease progression in myelodysplastic patients, and prediction of STI-571 responsiveness in chronic myeloid leukemia patients at molecular level.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)